Paper11029005
Immune control of HIV-1 after early treatment of acute infection.
Rosenberg ES and 9 others. Nature, 2000. Cited by 783 papers, by iCite.
Cite this record
ConductScience Library. Immune control of HIV-1 after early treatment of acute infection. Papers, record 11029005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11029005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| HIV-1 | Major topic |
| Acute Disease | |
| Adult | |
| CD4-Positive T-Lymphocytes | |
| CD8-Positive T-Lymphocytes | |
| Drug Administration Schedule | |
| Drug Therapy, Combination | |
| Gene Products, gag | |
| Humans | |
| Male | |
| Pilot Projects | |
| RNA, Viral | |
| T-Lymphocytes, Helper-Inducer | |
| Viral Load | |
| Viremia |
Source PubMed
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00058734 | Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients | Background | ClinicalTrials.gov | |
| NCT00125099 | Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection | Background | ClinicalTrials.gov | |
| NCT00183261 | Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection | Background | ClinicalTrials.gov | |
| NCT02042248 | A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004 | Background | ClinicalTrials.gov | |
| NCT02208167 | Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy | Background | ClinicalTrials.gov |
Cited by296
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 783 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42698968 | How past transient viremia shape natural killer cells' antibody-dependent functions in youth with perinatal HIV. | iScience | 2026 | https://conductscience.org/library/papers/42698968 | PubMed |
| 42492499 | Feasibility, Acceptability, and Test Performance of Point-of-Care Nucleic Acid Tests for HIV Testing and Viral Load Monitoring in the United States: Prospective Longitudinal Mixed-Methods Study. | JMIR Res Protoc | 2026 | https://conductscience.org/library/papers/42492499 | PubMed |
| 41282862 | CD8+ T cell recall cytotoxicity during chronic treated HIV-1 infection is associated with limited reservoir size and activity. | medRxiv | 2025 | https://conductscience.org/library/papers/41282862 | PubMed |
| 40953113 | Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV. | PLoS Comput Biol | 2025 | https://conductscience.org/library/papers/40953113 | PubMed |
| 40408432 | Transmitted/founder (T/F) HIV-1 derived from sexual contact exhibits greater transmission fitness in human cervical tissue than T/F HIV-1 from blood-to-blood contact: Unique glycan profiles on T/F envelopes associated with transmission phenotypes. | PLoS Pathog | 2025 | https://conductscience.org/library/papers/40408432 | PubMed |
| 40105005 | Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children. | Curr Opin HIV AIDS | 2025 | https://conductscience.org/library/papers/40105005 | PubMed |
| 39976231 | Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection. | Elife | 2025 | https://conductscience.org/library/papers/39976231 | PubMed |
| 39504491 | Rapid viral suppression using integrase inhibitors during acute HIV-1 infection. | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/39504491 | PubMed |
| 39466203 | Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection. | J Exp Med | 2024 | https://conductscience.org/library/papers/39466203 | PubMed |
| 38932264 | Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection. | Viruses | 2024 | https://conductscience.org/library/papers/38932264 | PubMed |
| 38808136 | Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/38808136 | PubMed |
| 38620211 | Current situation in the development of a preventive HIV vaccine. | Enferm Infecc Microbiol Clin | 2005 | https://conductscience.org/library/papers/38620211 | PubMed |
| 38032851 | Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency. | PLoS Pathog | 2023 | https://conductscience.org/library/papers/38032851 | PubMed |
| 37949070 | Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/37949070 | PubMed |
| 36851349 | Cohort-Specific Peptide Reagents Broaden Depth and Breadth Estimates of the CD8 T Cell Response to HIV-1 Gag Potential T Cell Epitopes. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36851349 | PubMed |
| 36541802 | Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. | J Virol | 2023 | https://conductscience.org/library/papers/36541802 | PubMed |
| 36207834 | Significance of initiating antiretroviral therapy in the early stage of HIV infection. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2022 | https://conductscience.org/library/papers/36207834 | PubMed |
| 35711433 | NK Cells, Monocytes and Macrophages in HIV-1 Control: Impact of Innate Immune Responses. | Front Immunol | 2022 | https://conductscience.org/library/papers/35711433 | PubMed |
| 34983387 | Application of quantile mixed-effects model in modeling CD4 count from HIV-infected patients in KwaZulu-Natal South Africa. | BMC Infect Dis | 2022 | https://conductscience.org/library/papers/34983387 | PubMed |
| 34961509 | Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection. | BMC Med Ethics | 2021 | https://conductscience.org/library/papers/34961509 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11029005
GET https://conductscience.org/api/papers/v1/11029005/cited_by?page=2